Levosimendan comes of age: twenty years in clinical use
نویسندگان
چکیده
منابع مشابه
After 20 years, liver transplantation comes of age.
WHrT£ OJ. ed. Cydosporin A: Proccedinp of the IntenutiotW Symposium. Cambridp. Amsterdam: Elsevier Biomedic:al Publishen; 1912:3544. 2. KAHAN BD. RJED M. NEWBEaGEa J. Phannacokinetica of eyeloaporine in hullWl rcnal transplantation. Tran."umt Prot:. 1983;15:446-53. 3. WHrT£ OJ. Cyeiosporin A: clinical phU1lUlC01OU and therapeutic p0tential Drop. 1982;14:322-34. 4. KAMAN BD. Mcctinc Report: the ...
متن کاملNitric oxide signaling comes of age: 20 years and thriving.
a Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas and Instituto “Reina Sofía” de Investigaciones Nefrológicas, Ramiro de Maeztu, 9, Madrid E-28040, Spain b The Johns Hopkins University School of Medicine, 950 Ross Bldg., 720 Rutland Ave., Baltimore, MD 21205, USA c Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medica...
متن کاملThe formative years: medical ethics comes of age.
When the Journal of Medical Ethics first appeared in April 1975, the prospects of success seemed uncertain. There were no scholars specialising in the field, the readership could not be guaranteed, and the medical profession itself seemed, at the very least, ambivalent about a subject thought by many to be the province of doctors alone, to be acquired through an apprenticeship model, and certai...
متن کاملEvidence-based use of levosimendan in different clinical settings.
Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischaemic effect. The documentation regarding levosimendan is one of the largest ever on the safety and efficacy of a new pharmacologic...
متن کاملClinical research in pulmonary hypertension comes of age.
The first randomized clinical trial with epoprostenol in patients with pulmonary arterial hypertension (PAH) was published 18 years ago.1 This trial was the first in a series of controlled clinical trials which subsequently defined the current therapeutic approach to this devastating disease.2 That these outstanding advances could be achieved in such a short period of time is the result of basi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Research Journal
سال: 2020
ISSN: 2451-4101,2451-2591
DOI: 10.5603/mrj.a2020.0036